

# Thomas Aparicio

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1837410/thomas-aparicio-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107 papers	1,974 citations	24 h-index	41 g-index
119 ext. papers	2,540 ext. citations	4.4 avg, IF	4.42 L-index

#	Paper	IF	Citations
107	Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 97-104	3.3	180
106	Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1464-70	2.2	155
105	Genomic Profiling of Small-Bowel Adenocarcinoma. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1546-1553	13.4	101
104	Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment <b>2019</b> , 7, 74		91
103	Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	84
102	Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 71, 249-57	7	81
101	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1740-1746	7.5	65
100	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). <i>European Journal of Cancer</i> , <b>2020</b> , 141, 62-81	7.5	65
99	Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa. <i>Gastroenterology</i> , <b>2004</b> , 126, 499-510	13.3	59
98	Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. <i>Gut</i> , <b>2020</b> , 69, 531-539	19.2	59
97	Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. <i>Cancer</i> , <b>2011</b> , 117, 1422-8	6.4	56
96	Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study. <i>Oncology</i> , <b>2011</b> , 81, 395-402	3.6	56
95	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 674-681	2.2	52
94	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2983-93	7.5	45
93	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. <i>JAMA Oncology</i> , <b>2018</b> , 4, e173695	13.4	37
92	Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 15-19	3.3	35
91	Small Bowel Adenocarcinoma. <i>Gastroenterology Clinics of North America</i> , <b>2016</b> , 45, 447-57	4.4	35

90	Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 245-50	3.3	34
89	FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4000-4000	2.2	33
88	Colorectal cancer care in elderly patients: Unsolved issues. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1112-8	3.3	30
87	Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2017</b> , 74, 98-108	7.5	28
86	Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2016</b> , 40, 154-60	2.4	27
85	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 285-296	7.5	26
84	COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 597-603	3.3	24
83	Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. <i>International Journal of Colorectal Disease</i> , <b>2015</b> , 30, 1305-10	3	23
82	Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 967-977	7.5	22
81	Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey. <i>Oncologist</i> , <b>2019</b> , 24, e1351-e1359	5.7	20
80	Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. <i>European Journal of Cancer</i> , <b>2018</b> , 98, 1-9	7.5	20
79	PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 206-7	3.3	19
78	Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. <i>European Journal of Surgical Oncology</i> , <b>2019</b> , 45, 331-335	3.6	18
77	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , <b>2019</b> , 46, 94-104	8.8	17
76	High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer. <i>Journal of Geriatric Oncology</i> , <b>2014</b> , 5, 384-8	3.6	16
75	Diagnostic performance of gait speed, G8 and G8 modified indices to screen for vulnerability in older cancer patients: the prospective PF-EC cohort study. <i>Oncotarget</i> , <b>2017</b> , 8, 50393-50402	3.3	16
74	Preferences about information and decision-making among older patients with and without cancer. <i>Age and Ageing</i> , <b>2017</b> , 46, 665-671	3	15
73	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , <b>2019</b> , 115, 97-106	7.5	15

72	Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: A population-based cohort and international multicentre cohort study. <i>EBioMedicine</i> , <b>2019</b> , 41, 276-285	8.8	15
71	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 424-428	8.7	15
70	Comparison of Mobility Indices for Predicting Early Death in Older Patients With Cancer: The Physical Frailty in Elderly Cancer Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2020</b> , 75, 189-196	6.4	15
69	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4745-4753	12.9	14
68	Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database. <i>Targeted Oncology</i> , <b>2017</b> , 12, 805-814	5	13
67	Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. <i>International Journal of Colorectal Disease</i> , <b>2018</b> , 33, 1125-1130	3	12
66	Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2018</b> , 41, 73-80	2.7	12
65	Safety and efficacy of palliative systemic chemotherapy combined with colorectal self-expandable metallic stents in advanced colorectal cancer: A multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2016</b> , 40, 230-8	2.4	10
64	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 305-307	3.3	10
63	Obesity survival paradox in cancer patients: Results from the Physical Frailty in older adult cancer patients (PF-EC) study. <i>Clinical Nutrition</i> , <b>2019</b> , 38, 2806-2812	5.9	10
62	High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2782-8	6.1	9
61	The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the ACSCrizotinib Program. <i>Targeted Oncology</i> , <b>2021</b> , 16, 381-388	5	9
60	Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3242-3250	2.2	9
59	Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD. <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 1255-1262	3.6	8
58	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 408-410	3.3	8
57	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 1153-1161	4	7
56	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). <i>European Journal of Cancer</i> , <b>2021</b> , 150, 232-239	7.5	7
55	Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2020</b> , 15, e0230914	3.7	7

54	Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 493-505	3.3	6
53	Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study. <i>Therapeutic Advances in Gastroenterology</i> , <b>2018</b> , 11, 1756283X1875626	4.7	6
52	Adjuvant chemotherapy by FOLFOX for gastric hepatoid adenocarcinoma. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 1135-6	3.3	6
51	GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4154-TPS4154	2.2	6
50	Development, validation and clinical impact of a prediction model for 6-month mortality in older cancer patients: the GRADE. <i>Aging</i> , <b>2020</b> , 12, 4230-4246	5.6	6
49	Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). <i>Radiotherapy and Oncology</i> , <b>2019</b> , 140, 84-89	5.3	5
48	Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 141, 143-151	7.5	5
47	Magnetic resonance imaging diffusion-weighted imaging for diagnosis of a gastric hepatoid adenocarcinoma. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 174	3.3	5
46	PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3541-3541	2.2	5
45	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1498-1502	3.3	4
44	Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 306-308	3.3	4
43	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab □ Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 420-426	3.3	4
42	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 97, 102202	14.4	4
41	Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 1731-1742	7.5	4
40	Prognostic value of the PrP-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. <i>Oncolmmunology</i> , <b>2021</b> , 10, 1940674	7.2	4
39	Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 799-804	3.6	3
38	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3515-3515	2.2	3
37	Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 285-290	3.8	2

36	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 957-962	8.7	2
35	Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study. <i>European Journal of Cancer</i> , <b>2019</b> , 123, 92-100	7.5	2
34	Primary prophylactic granulocyte colony-stimulating factor (G-CSF) in Gilbert's disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3614-3614	2.2	2
33	Colorectal cancer (CRC) patients surveyed by 18FDG PET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3520-3520	2.2	2
32	Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 350-350	2.2	2
31	Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcSIP program.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2504-2504	2.2	2
30	Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3570-3570	2.2	2
29	Effect of lockdown on digestive system cancer care amongst older patients during the first wave of COVID-19: The CADIGCOVAGE multicentre cohort study. <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	2
28	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRODIGE 71 - (FFCD 1710) phase III study. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1143-1147	3.3	2
27	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 496-500	9.7	2
26	Prognostic factors of recurrence of colorectal cancers with microsatellite instability after curative resection: An AGEO retrospective multicenter study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3536-3536	2.2	1
25	Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3601-3601	2.2	1
24	The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: Results from the AcSIP crizotinib program.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4054-4054	2.2	1
23	Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3550-3550	2.2	1
22	Personalized four-category staging for predicting prognosis in patients with small bowel Adenocarcinoma: an international development and validation study. <i>EBioMedicine</i> , <b>2020</b> , 60, 102979	8.8	1
21	Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab treatment for metastatic melanoma: a case report. <i>Annals of Palliative Medicine</i> , <b>2021</b> ,	1.7	1
20	MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
19	Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer. <i>BMC Medical Research Methodology</i> , <b>2021</b> , 21, 14	4.7	1



18	Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
17	Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 922-932	18.8	0
16	Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. <i>Biomedicines</i> , <b>2022</b> , 10, 1211	4.8	0
15	Colorectal Cancer in Older Adults: Systemic Treatments <b>2020</b> , 701-711		
14	Tumors: Colorectal <b>2021</b> , 5222-5234		
13	Colorectal Cancer in Older Adults: Systemic Treatments <b>2018</b> , 1-11		
12	Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3568-3568	2.2	
11	BIONADEGE: Genomic profiling of small bowel adenocarcinoma from the NADEGE prospective cohort.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4140-4140	2.2	
10	Implementation of complex perioperative intervention in older patients with cancer (IMPROVED program).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS11630-TPS11630	2.2	
9	Classic or simplified LV5FU2 regimen: Multivariate analysis from a phase III study in metastatic colorectal cancer in elderly patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3550-3550	2.2	
8	Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15034-e15034	2.2	
7	PRODIGE 34 ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS3628-TPS3628	2.2	
6	Reply to M. Mo et al. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2452-2453	2.2	
5	Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 40-50	7.5	
4	Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis <b>2020</b> , 15, e0230914		
3	Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis <b>2020</b> , 15, e0230914		
2	Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis <b>2020</b> , 15, e0230914		
1	Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis <b>2020</b> , 15, e0230914		

